Nancy Ratner PhD


Nancy Ratner PhD
ProfessorCollege of Medicine--UCnancy.ratner@cchmc.org
Room R-2325, MLC 7013 3333 Burnet Ave Cincinnati OH 452293039
Phone:(513) 636-9469Fax: (513) 636-3549
  • Molecular Biology and Cancer Genetics

General Research Interest

Central- Brain and peripheral nerve tumors and Neurofibromatosis

Research Description

The long term interest of the Ratner laboratory is to define the interactions between glial cells and axons during nervous system development and how those interactions go awry in disease, with the goal of providing novel therapies to patients with nervous system diseases. Neurofibromatosis type 1 (NF1) is an inherited autosomal dominant disorder (1:3500 humans) that involves the formation of many nerve-associated tumors and other non-tumor related problems. Neurofibromatosis type 2 (NF2) involves the development of Schwannomas, benign tumors composed of Schwann cells (peripheral glial cells). Elucidating the mechanisms by which the nerve-associated tumors arise in both diseases can not only lead to the development of therapy for NF1 and NF2 patients, but can also useful in providing information about non-inherited nervous system cancers.

Current Publications

  • Moriarity BS, Otto GM, Watson AL, Choi K, Collins MH, Wallace M, Webber BR, Forster CL, Rizzardi AE, Schmechel SC, Ratner N, Largaespada DA, Rahrmann EPTrp53 haploinsufficiency modifies EGFR-driven peripheral nerve sheath tumorigenesis.Am J Pathol 184 2082-98 7/1/2014
  • Watson AL, Anderson LK, Greeley AD, Keng VW, Rahrmann EP, Halfond AL, Powell NM, Collins MH, Rizvi T, Moertel CL, Ratner N, Largaespada DACo-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.Oncotarget 5 1502-14 3/30/2014
  • Ehrman LA, Nardini D, Ehrman S, Rizvi TA, Gulick J, Krenz M, Dasgupta B, Robbins J, Ratner N, Nakafuku M, Waclaw RRThe protein tyrosine phosphatase Shp2 is required for the generation of oligodendrocyte progenitor cells and myelination in the mouse telencephalon.J Neurosci 34 3767-78 3/5/2014
  • Widemann BC, Acosta MT, Ammoun S, Belzberg AJ, Bernards A, Blakeley J, Stevenson D, Stewart DR, Ullrich N, Bakker AC, Morrison H, Bretscher A, Cichowski K, Clapp DW, Dombi E, Evans GD, Ferner R, Fernandez-Valle C, Fisher MJ, Giovannini M, Gutmann DH, Hanemann CO, Hennigan R, Huson S, Ingram D, Kissil J, Korf BR, Legius E, Packer RJ, McClatchey AI, McCormick F, North K, Pehrsson M, Plotkin SR, Ramesh V, Ratner N, Schirmer S, Sherman L, Schorry ECTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.Am J Med Genet A 164A 563-78 3/1/2014
  • Brundage ME, Tandon P, Eaves DW, Williams JP, Miller SJ, Hennigan RH, Jegga A, Cripe TP, Ratner NMAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.Oncogene in press 2/10/2014
  • Wu J, Patmore DM, Jousma E, Eaves DW, Breving K, Patel AV, Schwartz EB, Fuchs JR, Cripe TP, Stemmer-Rachamimov AO, Ratner NEGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors.Oncogene 33 173-80 1/9/2014
  • Guo L, Lee AA, Rizvi TA, Ratner N, Kirschner LSThe protein kinase A regulatory subunit R1A (Prkar1a) plays critical roles in peripheral nerve development.J Neurosci 33 17967-75 11/13/2013
  • Guo L, Moon C, Zheng Y, Ratner NCdc42 regulates Schwann cell radial sorting and myelin sheath folding through NF2/merlin-dependent and independent signaling.Glia 61 1906-21 11/1/2013
  • Robinson AP, Miller SD, Cancelas JA, Stemmer-Rachamimov AO, Ratner N, Mayes DA, Rizvi TA, Titus-Mitchell H, Oberst R, Ciraolo GM, Vorhees CVNf1 loss and Ras hyperactivation in oligodendrocytes induce NOS-driven defects in myelin and vasculature.Cell Rep 4 1197-212 9/26/2013
  • Rahrmann EP, Watson AL, Keng VW, Choi K, Moriarity BS, Beckmann DA, Wolf NK, Sarver A, Collins MH, Moertel CL, Wallace MR, Gel B, Serra E, Ratner N, Largaespada DAForward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.Nat Genet 45 756-66 7/1/2013
  • Choi K, Conboy CB, Greeley AD, Halfond AL, Anderson LK, Wahl BR, Keng VW, Rizzardi AE, Forster CL, Collins MH, Sarver AL, Wallace MR, Schmechel SC, Ratner N, Largaespada DA, Watson AL, Rahrmann EP, Moriarity BSCanonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.Cancer Discov 3 674-89 6/1/2013
  • Plotkin SR, Blakeley JO, Evans DG, Hanemann CO, Hulsebos TJ, Hunter-Schaedle K, Kalpana GV, Korf B, Messiaen L, Papi L, Ratner N, Sherman LS, Smith MJ, Stemmer-Rachamimov AO, Vitte J, Giovannini MUpdate from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria.Am J Med Genet A 161A 405-16 3/1/2013
  • Hennigan RF, Moon CA, Parysek LM, Monk KR, Morfini G, Berth S, Brady S, Ratner NThe NF2 tumor suppressor regulates microtubule-based vesicle trafficking via a novel Rac, MLK and p38(SAPK) pathway.Oncogene 32 1135-43 2/28/2013
  • Rizvi TA, Brundage ME, Eaves D, Widemann B, Kim MO, Dombi E, Sabo J, Hardiman Dudley A, Niwa-Kawakita M, Page GP, Giovannini M, Aronow BJ, Cripe TP, Ratner N, Jessen WJ, Miller SJ, Jousma E, Wu JMEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.J Clin Invest 123 340-7 1/2/2013
  • Prada CE, Jousma E, Rizvi TA, Wu J, Dunn RS, Mayes DA, Cancelas JA, Dombi E, Kim MO, West BL, Bollag G, Ratner NNeurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition.Acta Neuropathol 125 159-68 1/1/2013
  • Guo L, Moon C, Niehaus K, Zheng Y, Ratner NRac1 controls Schwann cell myelination through cAMP and NF2/merlin.J Neurosci 32 17251-61 11/28/2012
  • Patmore DM, Welch S, Fulkerson PC, Wu J, Choi K, Eaves D, Kordich JJ, Collins MH, Cripe TP, Ratner NIn vivo regulation of TGF-β by R-Ras2 revealed through loss of the RasGAP protein NF1.Cancer Res 72 5317-27 10/15/2012
  • Gutmann DH, Parada LF, Silva AJ, Ratner NNeurofibromatosis type 1: modeling CNS dysfunction.J Neurosci 32 14087-93 10/10/2012
  • Cripe TP, Miller SJ, Ratner N, Patel AV, Eaves D, Jessen WJ, Rizvi TA, Ecsedy JA, Qian MG, Aronow BJ, Perentesis JP, Serra ERas-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.Clin Cancer Res 18 5020-30 9/15/2012
  • Acosta MT, Bearden CE, Castellanos FX, Castellanos XF, Cutting L, Elgersma Y, Gioia G, Gutmann DH, Lee YS, Legius E, Muenke M, North K, Parada LF, Ratner N, Hunter-Schaedle K, Silva AJThe Learning Disabilities Network (LeaDNet): using neurofibromatosis type 1 (NF1) as a paradigm for translational research.Am J Med Genet A 158A 2225-32 9/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu